Literatur
Dupont AW, Dupont HL (2011) The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol 8: 523–531
Kruis W, Fric P, Pokrotnieks J et al (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617–1623
D’Haens G, Sandborn WJ, Feagan BG et al (2007) A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132: 763–786
Bloom SM, Bijanki VN, Nava GM et al (2011) Commensal bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe 9: 390–403
Valeur N, Engel P, Carbajal N et al (2004) Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol 70: 1176–1181
Liu Y, Fatheree NY, Mangalat N et al (2010) Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 299: G1087–G1096
Livingston M, Loach D, Wilson M et al (2010) Gut commensal Lactobacillus reuteri 100-23 stimulates an immunoregulatory response. Immunol Cell Biol 88: 99–102
Miele E, Pascarella F, Giannetti E et al (2009) Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104: 437–443
Interessenkonflikt
Der Autor erklärt, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmitz, F. Rektale Einläufe mit Lactobacillus reuteri bei Kindern mit distaler Colitis ulcerosa. Gastroenterologe 8, 56–57 (2013). https://doi.org/10.1007/s11377-012-0741-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11377-012-0741-3